Shots:

• The US FDA has granted FT designation to Alector’s AL101 to treat patients with progranulin gene mutations causative of frontotemporal dementia (FTD-GRN)- currently being evaluated in P-I study in healthy volunteers
• The FDA’s FT designation is designed to facilitate the development and expedite the review of therapies for serious conditions targeting unmet medical needs of patients
• AL101 is a mAb- designed to restore levels of progranulin in the CNS- currently in development for FTD-GRN- AD and PD and has received FDA’s ODD for FTD-GRN in July’2019

Click here ­to­ read full press release/ article | Ref: Alector | Image: Alector